Clinical trial
Study Evaluating Prevenar Vaccine in Healthy Infants
NCT00276107 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00276107 |
|---|---|
| Title | Study Evaluating Prevenar Vaccine in Healthy Infants |
| Official title | An Open-Label Trial of the Immunogenicity and Safety of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine [Diphteria CRM197 Protein Conjugate]) in Healthy Infants at 2, 4 and 6 Months of Age |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pneumococcal Infections |
| Intervention type | Biological |
| Interventions | Prevenar |
| Enrollment | 200 |
| Start date | Dec 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Jan 12, 2006 |
| Last update posted | Jul 29, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: